Showing results (51-60 of 317) with videos related to
Sort By:
Pageof 32
Cancer Immunology, Immunotherapy : CII|January 1, 1990
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectorsM Sensi, L Grazioli, M Rodolfo, et al.International Journal of Clinical & Laboratory Research|January 1, 1997
T-cell recognition of melanoma antigens and its therapeutic applicationsC Castelli, L Rivoltini, A Mazzocchi, et al.Melanoma Research|August 1, 1991
An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysisA Mazzocchi, M Rodolfo, G Parmiani, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acidG Pratesi, M Rodolfo, G Rovetta, et al.European Journal of Immunology|October 1, 1998
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cellsZ Wang, F Arienti, G Parmiani, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumoursM Rodolfo, C Bassi, C Salvi, et al.International Journal of Cancer|April 1, 1994
Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profilesC Maccalli, R Mortarini, G Parmiani, et al.Cancer Research|November 24, 2001
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cellsG Pietra, R Mortarini, G Parmiani, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Vaccination of patients with solid tumoursG Parmiani, L Pilla, C Castelli, et al.Cancer Chemotherapy and Pharmacology|January 1, 1988
Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicinR Supino, M Mariani, E Prosperi, et al.Pageof 32